Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL689733 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL3674503 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL19080644 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL689912 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL1303907 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL7882438 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL8989612 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL589712 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| Hydrochloric Acid SCHEMBL350474 | 0.98 | ATM (0.57) | ATMPIK3CDGAAALDH1A1ACE | |
| Hydrochloric Acid SCHEMBL2147938 | 0.98 | ATM (0.57) | ATMPIK3CDGAAALDH1A1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2023272720-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS OF PD-L1 INTERACTIONS | Ascletis BioScience Co., Ltd (CN) | 2023-01-05 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
| CN-111989321-A | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2020-11-24 | — | — | CN | disclosed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | disclosed |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | AMGEN INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200223829-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2020-07-16 | — | — | US | disclosed |
| WO-2010026096-A1 | 7-(PIPERAZINE-1-YMETHYL)-1H-INDOLE-2-CARBOXYLIC ACID (PHENYL)-AMIDE DERIVATIVES AND ALLIED COMPOUNDS AS P38 MAP KINASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026096-A1 | 7-(PIPERAZINE-1-YMETHYL)-1H-INDOLE-2-CARBOXYLIC ACID (PHENYL)-AMIDE DERIVATIVES AND ALLIED COMPOUNDS AS P38 MAP KINASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
| US-20080234263-A1 | Quinazoline Derivatives | ASTRAZENECA (SE) | 2008-09-25 | — | — | US | disclosed |
| CN-1275051-A | Method for improving the freezing tolerance of plant | UNIV DU QUEBEC A MONTREAL (CA) | 2000-11-29 | — | — | CN | disclosed |
| US-5523413-A | Process for optically active 2-alkyl-2,5-diazabicyclo[2.2.1] heptanes | PFIZER INC. (US) | 1996-06-04 | — | — | US | disclosed |
| US-5475117-A | Process for optically active 2-alkyl-2,5-diazabicyclo[2.2.1]heptanes | PFIZER, INC. (US) | 1995-12-12 | — | — | US | disclosed |
| US-5371235-A | Process for optically active 2-alkyl-2,5-diazabicyclo[2.2.1]heptanes | PFIZER INC. (US) | 1994-12-06 | — | — | US | disclosed |
| US-5157125-A | Optically active 2-alkyl-2,5-diazabicyclo[2.2.1]heptanes | PFIZER INC. (US) | 1992-10-20 | — | — | US | disclosed |
| US-5095121-A | Process for optically active 2-alkyl-2,5-diazabicyclo(2.2.1)heptanes | PFIZER INC (US) | 1992-03-10 | — | — | US | disclosed |
| US-5013839-A | Process for optically active 2-alkyl-2,5-diazabicyclo(2.2.1) heptanes | PFIZER INC. (US) | 1991-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234263-A1 | Quinazoline Derivatives | EGFR, ERBB2, ERBB3 | ATM 560/4885PIK3CD 272/4885GAA 2323/4885 |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | ATM 3953/4885PIK3CD 1410/4885GAA 2874/4885 |
| US-20200262837-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ATM 3528/4885PIK3CD 253/4885GAA 1367/4885 |
| US-20200223829-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | ATM 3953/4885PIK3CD 1410/4885GAA 2874/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ATM 3528/4885PIK3CD 253/4885GAA 1367/4885 |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | TNNI3, TNNT2, TNNC1 | ATM 3596/4885PIK3CD 2436/4885GAA 2907/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ATM 3528/4885PIK3CD 253/4885GAA 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.